Investing.com -- Roche (SIX:RO) on Thursday said it expects high single-digit growth in core profit for 2025, following a strong performance in 2024 driven by strong sales in both ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Roche's Q4 results and innovative advancements make it a strong pick. Its late-stage pipeline supports our belief that there ...

J.P. Morgan analyst Richard Vosser maintained a Sell rating on Roche Holding AG (RHHVF – Research Report) today and set a price target of ...

Roche's drug portfolio shows promise, but mixed indicators reveal uncertainties. Check out the risks, opportunities, and ...

Barclays analyst Emily Field maintained a Hold rating on Roche Holding AG (RHHVF – Research Report) today and set a price target of CHF290.00.

The weight-loss drug market is heating up, with Swiss company Roche making a bold move by acquiring Carmot Therapeutics for up to $3.1 billion in 2023. This investment is aimed at accelerating its ...